2 weeks Ago By ABMN Staff
LPL Financial LLC increased its holdings in shares of RxSight, Inc. ( NASDAQ:RXST – Free Report ) by 3.6% during the fourth quarter, HoldingsChannel.
com reports. The fund owned 25,007 shares of the company’s stock after buying an additional 861 shares during the period. LPL Financial LLC’s holdings in RxSight were worth $860,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Fox Run Management L.L.
C. boosted its holdings in shares of RxSight by 47.2% during the 4th quarter.
Fox Run Management L.L.C.
now owns 29,458 shares of the company’s stock worth $1,013,000 after purchasing an additional 9,443 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of RxSight in the fourth quarter valued at approximately $213,000. Quantbot Technologies LP lifted its position in RxSight by 31.
7% during the fourth quarter. Quantbot Technologies LP now owns 33,444 shares of the company’s stock worth $1,150,000 after buying an additional 8,041 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in RxSight by 53.
6% during the fourth quarter. Thrivent Financial for Lutherans now owns 352,626 shares of the company’s stock worth $12,124,000 after buying an additional 122,989 shares during the last quarter. Finally, Telemark Asset Management LLC grew its holdings in RxSight by 6.
6% in the 4th quarter. Telemark Asset Management LLC now owns 321,000 shares of the company’s stock valued at $11,036,000 after buying an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 78.
78% of the company’s stock. Insider Activity at RxSight In other RxSight news, Director Tamara Fountain sold 7,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.
71, for a total transaction of $179,970.00. Following the sale, the director now owns 24,793 shares in the company, valued at $637,428.
03. This represents a 22.02 % decrease in their position.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, Director Shweta Maniar sold 3,519 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.
87, for a total value of $108,631.53. Following the completion of the sale, the director now directly owns 7,383 shares in the company, valued at $227,913.
21. This represents a 32.28 % decrease in their position.
The disclosure for this sale can be found here . Company insiders own 9.36% of the company’s stock.
Wall Street Analyst Weigh In Read Our Latest Report on RxSight RxSight Stock Down 1.6 % Shares of NASDAQ RXST opened at $14.20 on Tuesday.
RxSight, Inc. has a 52-week low of $13.50 and a 52-week high of $66.
54. The business’s 50 day moving average is $23.42 and its two-hundred day moving average is $34.
71. The firm has a market cap of $574.97 million, a price-to-earnings ratio of -17.
11 and a beta of 1.26. RxSight ( NASDAQ:RXST – Get Free Report ) last announced its earnings results on Tuesday, February 25th.
The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.
25). The firm had revenue of $40.21 million for the quarter, compared to analysts’ expectations of $40.
23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.
00%. Analysts anticipate that RxSight, Inc. will post -0.
7 EPS for the current fiscal year. About RxSight ( Free Report ) RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Featured Articles Want to see what other hedge funds are holding RXST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RxSight, Inc. ( NASDAQ:RXST – Free Report ).
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter ..
